(Q44608414)

4 December 2017

title

Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy (English)

1 reference

4 December 2017

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0090-8258(03)00464-5

18 March 2024

4

Carol Aghajanian

1 reference

4 December 2017

Amanda Hummer

2

1 reference

4 December 2017

Martee Hensley

5

1 reference

4 December 2017

Paul Sabbatini

6

1 reference

4 December 2017

Ennapadam Venkatraman

7

1 reference

4 December 2017

Mario M. Leitao

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14529671

18 March 2024

Don S. Dizon

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14529671

18 March 2024

David R. Spriggs

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14529671

18 March 2024

language of work or name

English

0 references

publication date

1 October 2003

1 reference

full work available at URL

4 December 2017

https://api.elsevier.com/content/article/PII:S0090825803004645?httpAccept=text/xml

1 reference

DOI

https://api.crossref.org/works/10.1016/S0090-8258(03)00464-5

https://api.elsevier.com/content/article/PII:S0090825803004645?httpAccept=text/plain

18 March 2024

1 reference

DOI

https://api.crossref.org/works/10.1016/S0090-8258(03)00464-5

18 March 2024

1 reference

4 December 2017

volume

91

1 reference

4 December 2017

issue

1

1 reference

4 December 2017

page(s)

123-129

1 reference

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

"Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900464-5

7 January 2021

Identifiers

DOI

1 reference

release_zfy37ktftjac5aps35zf35l3dy

4 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zfy37ktftjac5aps35zf35l3dy

24 November 2022

mapped directly with Wikidata item

1 reference